Vascular Endothelial Growth Factor Trap Suppresses Ovarian Function at All Stages of the Luteal Phase in the Macaque
article
OA: bronze
CC0
⤵ 1 in-corpus citation
AI-generated summary
Administering a VEGF Trap inhibitor during the early or midluteal phase of the macaque menstrual cycle significantly suppressed progesterone and estradiol, leading to altered LH and FSH levels and, in some cases, premature menstruation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
CONTEXT: Fertility is dependent on a functioning corpus luteum, the formation of which is associated with intense angiogenesis. The role of angiogenic factors, such as vascular endothelial growth factor (VEGF), in luteal function has yet to be defined in primates. OBJECTIVE: The objective of this study was to determine effects of inhibiting VEGF by a VEGF Trap, a receptor-based inhibitor, administered at the early or midluteal phase, on pituitary-ovarian function. DESIGN: Effects of a single injection of VEGF Trap at three doses in the early luteal phase or a single dose in the midluteal phase were investigated and compared with control cycles. SETTING: This work was conducted in the Primate Unit. PARTICIPANTS: Eleven stump-tailed macaques with regular ovulatory cycles participated in this study. VEGF Trap was well tolerated, and all completed the study. INTERVENTIONS: A single injection of VEGF Trap at a dose of 4, 1, or 0.25 mg/kg was administered in the early luteal phase or 1 mg/kg in the midluteal phase. Controls received vehicle or the constant region of human IgG. MAIN OUTCOME MEASURES: Changes in serum concentrations of progesterone, estradiol, LH, FSH, inhibin A, VEGF Trap, and menstrual bleeding were the main outcome measures. RESULTS: Early luteal treatment caused a significant attenuation of the normal serum progesterone and estradiol concentrations, followed by a marked increase in LH and FSH. Inhibin A was not significantly reduced. After 1- and 4-mg/kg doses, progesterone remained suppressed throughout the luteal phase, and premature menstruation occurred; whereas the response to the 0.25-mg/kg dose was transitory, and menstruation was at the normal time. Midluteal treatment also resulted in a significant suppression of progesterone secretion. CONCLUSIONS: VEGF is essential for both the development and maintenance of luteal function.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Angiogenesis and its control in the female reproductive system 2000
- Suppression of Follicular Maturation by Infusion of a Luteinizing Hormone-Releasing Hormone Agonist Starting during the Late Luteal Phase in the Stumptailed Macaque Monkey 1985
Cited by (1)
References (37)
- Angiogenesis and its control in the female reproductive system via openalex
- Suppression of Follicular Maturation by Infusion of a Luteinizing Hormone-Releasing Hormone Agonist Starting during the Late Luteal Phase in the Stumptailed Macaque Monkey via openalex
- doi:10.1677/joe.0.1680409 via openalex
- doi:10.1210/jcem-64-1-148 via openalex
- doi:10.1095/biolreprod67.4.1305 via openalex
- doi:10.1530/jrf.0.0800403 via openalex
- doi:10.1210/jcem.83.6.4884 via openalex
- doi:10.1016/s0015-0282(16)46509-x via openalex
- doi:10.1210/jcem.81.4.8636341 via openalex
- doi:10.1016/1043-2760(93)90115-u via openalex
- doi:10.1677/jme.0.0100245 via openalex
- doi:10.1210/jcem.77.2.8345049 via openalex
- doi:10.1095/biolreprod67.4.1180 via openalex
- doi:10.1210/jc.2004-1572 via openalex
- doi:10.1095/biolreprod50.4.888 via openalex
- doi:10.1073/pnas.172398299 via openalex
- doi:10.1210/jcem.85.6.6621 via openalex
- doi:10.1210/endo-121-2-612 via openalex
- doi:10.1210/endo.137.1.8536637 via openalex
- doi:10.1186/1477-7827-1-88 via openalex
- doi:10.1210/jc.77.5.1402 via openalex
- doi:10.1210/jcem.86.2.7181 via openalex
- doi:10.1111/j.1365-2265.1994.tb02504.x via openalex
- doi:10.1210/jcem.86.7.7662 via openalex
- doi:10.1095/biolreprod.102.006700 via openalex
- doi:10.1210/en.2004-0765 via openalex
- doi:10.1038/nm0398-336 via openalex
- doi:10.1093/molehr/6.11.993 via openalex
- doi:10.1210/endo.143.7.8896 via openalex
- doi:10.1210/jc.2004-0843 via openalex
- doi:10.1530/rep.0.1220085 via openalex
- doi:10.1053/beog.2000.0133 via openalex
- doi:10.1210/jcem.85.11.6942 via openalex
- doi:10.1210/jcem.84.4.5586 via openalex
- doi:10.1210/jc.2002-021516 via openalex
- doi:10.1016/s0015-0282(16)54537-3 via openalex
- doi:10.1210/endo.141.3.7369 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-11T06:25:09.493344+00:00
License: CC0
· commercial use OK